College Student Blogs. Click This Link: http://www.Bempowered2.com Enter Your Email...Watch The FREE VIDEO! http://youtu.be/zD6guFvx0No https://www.facebook.com/note.php?note_id=387848464582218
Caralluma
Fimbriata is widely acknowledged as the MOST POWERFUL weight loss and
appetite suppressant that is completely natural and 100% side effect
free! To learn all about Caralluma and what it means for YOU CLICK http://carallumaforyou.com/ To learn about the bestselling Caralluma product CLICK http://carallumaforyou.com/caralluma-actives
Ashford University's vibrant community of students and alumni consists of people from all walks of life, proving that achievement belongs to all of us. Their stories never cease to amaze and inspire. Though somewhat ordinary at first glance - working parents, active military, corporate ladder climbers - a deeper look into their lives often reveals the extraordinary.
To view Multimedia News Release, go to http://www.multivu.com/players/English/56781-ashford-university/
Yes! You heard that absolutely right. Plancess brings to you affordable 1 hour classes that will clear a number of your doubts, comprehensively. Excel in all engineering entrance exams with Plancess. Visit http://www.plancess.com to know more!
PR Newswire has released the results of its second deep dive analysis of its press release data, revealing once again that press releases that include multimedia assets garner significantly more visibility than text-only releases – up to 9.7 times more.
To view Multimedia News Release, go to http://www.multivu.com/players/English/59124-pr-newswire-visual-pr/
SIRO Clinpharm, a leading full service clinical research organization, unveiled its new brand identity on Friday. The new look affirms the recent transformation in the company’s business strategy.
“With the vast experience garnered over the past 16 years, SIRO was set to take a leap forward. With its customer centric leadership, we have built depth in various areas of competencies, leveraging our 4 pillars – people, processes, technologies and solutions,” said Dr. Gautam Daftary, founder and chairman, SIRO Clinpharm.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58672-SIRO-Clinpharm-unveils-new-brand-identity
Leading scientists have released the latest results of the large scale trials related to nuts consumption and health, particularly in myocardial infarction, stroke and cardiovascular diseases. Recent scientific studies show the benefits of regular intake of nuts, not only associated with cardiovascular health but also with renal function, diabetes, cognitive function, atherosclerosis, metabolic syndrome, inflammatory biomarkers, etc. It is important to highlight that scientific evidence demonstrates that eating nuts is not associated with a higher risk of weight gain, and even reinforce their importance as sources of key nutrients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62432-scientifically-proven-nuts-are-not-fattening
Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg® compared to biphasic insulin aspart 30, both administered twice-daily1.
Ryzodeg® is the first combination of two distinct insulin analogues, Tresiba® (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid® (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes2-4.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
http://www.TheFrackingTruthBook.com “The US will never run out of oil and natural gas. NEVER. Same goes for the rest of the world. Won’t happen,” says Dallas-based oil and gas executive Chris Faulkner in his new book, The Fracking Truth.“Faulkner’s book should be widely read before falling victim to hearsay and Hollywood-tainted brouhaha. Then decide, individually, how to consider fracking,” says Grady Harp a Top 100 Amazon and Hall of Fame Reviewer rating it ‘5 stars of 5’ possible.Available on Amazon, Barnes & Noble, iBookstore & BookMasters Distribution.Contact: Scott Lorenz of Westwind Book Marketing scottlorenz@WestWindCos.com http://www.book-marketing-expert.com 734.667.2090 or Traci Dakins, Stephenson Group TDakins@StephensonGroup.com 253.306.4006 Non Fiction
